Table 2. Cytotoxicity of IMGN632, X-ADC,... | American Society of Hematology

Table 2.

Cytotoxicity of IMGN632, X-ADC, and GO in primary AML samples

Sample no.	Patient status	BM blasts, %	MDR1 status	IMGN632 IC₉₀, pM	X-ADC IC₉₀, pM	GO IC₉₀, pM
39	Diagnosis	88	−	3.4	2.8	30
30	Diagnosis	28	+	3.6	2.8	300
35	Refractory	18	+	7	NT	1 000
9	Diagnosis	87	+	7.6	2.4	44
41	Diagnosis	90	+	9	NT	5 000
16	Relapsed	93	−	13	11	13
32	Diagnosis	83	+/−	13	2.3	2 500
31	Diagnosis	18	+/−	15	4.8	>10 000
12	Relapsed/refractory	91	+/−	18	7.9	1 200
13	Diagnosis	NT	−	18	10	NT
21	Diagnosis	80	NT	18	NT	2 000
37	Diagnosis	83	−	20	NT	2 000
45	Relapsed/refractory	90	+	26	14	30
36	Diagnosis	NT	+	40	NT	800
38	Diagnosis	95	+/−	40	19	30
28	Diagnosis	30	+	56	31	10 000

Sample no.	Patient status	BM blasts, %	MDR1 status	IMGN632 IC₉₀, pM	X-ADC IC₉₀, pM	GO IC₉₀, pM
39	Diagnosis	88	−	3.4	2.8	30
30	Diagnosis	28	+	3.6	2.8	300
35	Refractory	18	+	7	NT	1 000
9	Diagnosis	87	+	7.6	2.4	44
41	Diagnosis	90	+	9	NT	5 000
16	Relapsed	93	−	13	11	13
32	Diagnosis	83	+/−	13	2.3	2 500
31	Diagnosis	18	+/−	15	4.8	>10 000
12	Relapsed/refractory	91	+/−	18	7.9	1 200
13	Diagnosis	NT	−	18	10	NT
21	Diagnosis	80	NT	18	NT	2 000
37	Diagnosis	83	−	20	NT	2 000
45	Relapsed/refractory	90	+	26	14	30
36	Diagnosis	NT	+	40	NT	800
38	Diagnosis	95	+/−	40	19	30
28	Diagnosis	30	+	56	31	10 000

+, Greater than twofold shift in Syto16 in the presence of MDR1 inhibitor; +/−, up to twofold shift in Syto16 in the presence of MDR1 inhibitor; −, no shift; NT, not tested.